No profile data available.
OmniAb, Inc. (OABI) is a healthcare company in the blood cancer treatment drugs industry, based in EmeryVille, United States, with about 89 full-time employees.
It reported revenue of $18.67 million for fiscal year 2025, down 29.3% from fiscal year 2024, and net income of -$64.78 million. Its market capitalization was $696.42 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
OmniAb reported $18.67 million in revenue for fiscal year 2025, down 29.3% from $26.39 million in fiscal year 2024.
$696.42 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Vor Biopharma Inc. (VOR), Kura Oncology, Inc. (KURA), Corvus Pharmaceuticals, Inc. (CRVS), Sellas Life Sciences Group, Inc. (SLS).